A biomarker is a biological characteristic that can be used to gauge a disease’s existence, severity, or impact. Prostate-specific antigen (PSA) is a biomarker for prostate cancer. Researchers can immediately view a variety of biological analytics thanks to biomarkers.
The market worth of central nervous system biomarkers in 2021 was USD 4 billion, and it will be worth USD 8.7 billion by 2030, growing at a 9.0% CAGR during the forecast period.
The rise in the number of Alzheimer’s patients, considerable R&D in neurological biomarkers, increased demand for efficient therapy choices, and a greater emphasis on clinical biomarker trials are the main reasons boosting the market’s growth. Moreover, the market has expanded due to the rise in Parkinson’s disease patients. In the US, the 14th leading cause of mortality in Parkinson’s disease, according to the Centers for Disease Control and Prevention (CDC). Additionally, the Parkinson’s Foundation estimates that by 2030 there will be 1.2 million people living with the disease in the US.
Market Dynamics
Drivers
Trends in the Central Nervous System (CNS) Biomarkers Market are significantly impacted by rising disposable income and technological improvements. Demand-supply dynamics will also influence the development of the Central Nervous System (CNS) Biomarkers Market. The Central Nervous System (CNS) Biomarkers Market will grow as a result of government initiatives that benefit consumers and boost their purchasing power.
Restraints
A lack of technical experts and fluctuating raw material prices might restrict the growth of the Central Nervous System (CNS) Biomarkers Market. The COVID pandemic also hindered supply chain activity and stopped the Central Nervous System (CNS) Biomarkers Market.
Opportunity
The rising emphasis on forming strategic alliances among industry players and introducing new goods and technologies will boost the Central Nervous System (CNS) Biomarkers Market. The industry’s players are emphasizing on expanding their regional presence and maintaining a strong position in the Central Nervous System (CNS) Biomarkers Market. This will lead to a growth in the size of the Central Nervous System (CNS) Biomarkers Market during the forecast period.
Market Segmentation
On the basis of type, the CNS biomarker market is segmented into validation biomarkers, safety biomarkers, efficacy biomarkers, and others.
The Safety Biomarker led the entire market in 2020 due to increased usage at the preclinical stage and growing awareness of routine health checkups, depression, Parkinson’s disease, and multiple sclerosis. According to data published by a group of pharmaceutical companies in December 2020, 83% of the 24 enterprises questioned used safety markers during the clinical trial period.
On the basis of application, the CNS Biomarker market is segmented into personalized medicine, drug discovery & development, and others.
Personalized medicine has been determined that the most promising method for treating diverse illnesses. Major factors boosting the market are the rising incidence of brain and other nervous system cancers. As a result, several businesses are concentrating their efforts on developing ground-breaking drugs to treat neurological diseases.
On the basis of end-user, the market is segmented into hospitals & clinics, research centers, and diagnostic labs.
An aging population and a rise in cancer incidence from organophosphates are the main causes of the rising need for CNS biomarkers in diagnostic centers. The identification of various neurological diseases, as well as the tracking of disease progression, require biomarkers. As more techniques for early diagnosis are created, the demand for CNS biomarkers in diagnostic labs will increase.
Regional Insights
North America considerably ruled the regional market in 2020. Brain cancer was the second most frequently diagnosed disease in children and adolescents in 2021, with 27% and 21% of cases, respectively, according to the American Cancer Society. Additionally, as of August 2020, the American Cancer Society reports that USD 23.1 million has been allocated for clinical and cancer prevention research in the United States that is related to the brain.
The Asia Pacific regional market will develop at the highest rate due to factors including a sizable customer base, an increase in the prevalence of CNS diseases, and improved healthcare infrastructure. New central nervous system biomarkers may also be developed because of the region’s expanded research capacity and enhanced healthcare facilities.
Key Players
- AbaStarMDx Inc.
- Abiant, Inc.
- Thermo Fisher Scientific
- Merck & Co.
- Avacta Group plc
- Avid Radiopharmaceuticals Inc.
- Acumen Pharmaceuticals Inc.
- Diagenetic AsaG-Biosciences
- Merck KGaA
- Banyan Biomarkers
- Siemens AG
- Novartis
- Bio-Rad Laboratories, Inc.
- Biomeriux (Banyan Biomarkers Inc.)
The market worth of central nervous system biomarkers in 2021 was USD 4 billion, and it will be worth USD 8.7 billion by 2030, growing at a 9.0% CAGR during the forecast period. New technological advancements and their rising application in diagnosing a neurodegenerative illness are two important reasons driving the CNS biomarkers market. Furthermore, increased R&D, as well as successful clinical studies, contribute to the growth of the CNS biomarkers market.
